Arthrogen is an Amsterdam based biopharmaceutical company developing local gene therapy for inflammatory diseases, using viral mediated gene transfer. The first target indication is in the field of rheumatic diseases. The therapeutic vectors are derived from natural occurring adeno-associated viruses (AAV) that are not pathogenic in humans. The recombinant viruses are engineered to express therapeutic proteins or to express genes that can knock-down proteins that are involved in the pathogenesis of rheumatic diseases. Arthrogen BV was founded in 2005 as a joint venture between the Dubai Bone & Joint Center (DBAJ) in the United Arab Emirates and the Academic Medical Center (AMC) in Amsterdam, the Netherlands. Arthrogen’s aim is to develop adeno-associated viral mediated gene therapy for patients with rheumatic conditions. The company is based on the premises of the AMC/University of Amsterdam in Amsterdam.
Looking for a particular Arthrogen BV employee's phone or email?
Arthrogen BV Questions
The Arthrogen BV annual revenue was $6.6 million in 2026.
Arthrogen BV is based in Amsterdam, Nord-Holland.
The NAICS codes for Arthrogen BV are [541, 5417, 54, 541713, 54171].
The SIC codes for Arthrogen BV are [873, 87].
